Brind.

Genmab reported increased royalties from its DARZALEX collaboration with Johnson & Johnson, while UBS maintained a Buy rating on the company.

3 reports, 2 independent Updated Aug 26

Gone quiet

Reports: 3
Developments: 1
Repetition: 67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Genmab reported increased royalties from its DARZALEX collaboration with Johnson & Johnson, while UBS maintained a Buy rating on the company.

Who's involved

What this event is mainly about

Genmab Johnson & Johnson UBS

Keep exploring

The entities involved

Genmab
Danish healthcare company
- Genmab, a Danish biotechnology company, granted stock units and warrants via its Board of Directors on September 1, 2026.Thu 21:07
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
- P&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.Mon 00:50
- Johnson & Johnson separated its Consumer Health business into Kenvue on August 25, 2025.Sun 04:04
UBS
Swiss multinational investment bank and financial services company
- The Trump administration threatens tariffs on Switzerland, leading Switzerland to seek a new trade agreement with the US.Mon 00:13
- Following the acquisition of Credit Suisse, the Swiss parliament proposed new banking regulations for UBS.Sun 10:25

Coverage

Newest first; wire copies grouped

Aug 26yahoo.com
Jul 10Insider MonkeyUBS Maintains a Buy on Genmab (GMAB) With a DKK2,500 PT Genmab A/S (NASDAQ:GMAB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 25, UBS analyst Xian Deng maintained a Bu

1 more outlet ran the same wire story

Aug 26insidermonkey.com